Thrombotic Microangiopathy (TMA) Associated with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a serious complication that is associated with increased morbidity, related to multiple organ failure, with increased mortality in transplant patients. The incidence and evolution of TMA, especially in the adult population, is unclear due to the lack of early systematic screening and clear criteria for its diagnosis. For this reason, we designed this protocol to study the incidence and evolution of TMA Associated with allogeneic HSCT in adult patients from Argentina.
This is a prospective multicenter non-interventional observational study that will include sites that perform routine screening using harmonized definitions and diagnostic criteria during the first 100 days post-HSCT (screening period). All patients entering the study (HSCT accessible population), regardless of suspicion or diagnosis of TMA, will be followed every 3 months up to 12 months after transplant to evaluate secondary outcomes (follow-up period).
Study Type
OBSERVATIONAL
Enrollment
200
Instituto de Trasplantes de Alta Complejidad (ITAC)
Buenos Aires, Argentina
RECRUITINGIncidence of TMA in adult patients receiving allogeneic HSCT in specialized centers in Argentina
The incidence of TMA will be assessed by the presence of ≥ 4/diagnostic laboratory/clinical markers present in 2 successive assessments within 14 days or if TMA is identified histologically by tissue biopsy up to day 100 post-transplant. Laboratory/clinical diagnostic markers (Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated published by Schoettler et al Transplant Cell Ther. 2023) are: 1-Elevated schistocytes in peripheral blood; 2-LDH above the upper limit of normal; 3-De novo thrombocytopenia or requirement for platelet transfusion; 4-De novo anemia or requirement for red blood cell transfusion; 5-High blood pressure (≥140/90); 6-Protein/creatinine ratio \> 1 mg/mg or proteinuria ≥ 30 mg/dl in a random sample; 7-sC5b-9 above the upper limit of normal.
Time frame: 100 days post-HSCT (screening period)
Overall Survival
Proportion of TMA patients alive at each evaluation time frame
Time frame: 3, 6, 9, 12 months (follow-up period)
Non-relapse Mortality
Proportion of TMA patients that have died (death from any cause with exception of death due to progression or recurrence of the underlying disease) at each evaluation time frame
Time frame: 3, 6, 9, 12 months (follow-up period)
Proportion of patients achieving TMA response
TMA response is defined through the presence of response criteria (platelet count ≥ 50,000/mm3, lactate dehydrogenase \< 1.5 upper limit of normal, absence of schistocytes (if present at baseline) and increase in eGFR ≥ 30% from baseline or interruption of dialysis for patients on dialysis treatment at baseline), at each evaluation time frame
Time frame: 3, 6, 9, 12 months (follow-up period)
Proportion of patients free of transfusion requirement
Assessed through the non-requirement of transfusion of red blood cells or platelets indicated for the management of TMA for ≥ 28 days, at each evaluation time frame (Transfusions required for causes other than TMA will not be considered within the evaluation of this endpoint)
Time frame: 3, 6, 9, 12 months (follow-up period)
Proportion of patients with high-risk TMA,
Assessed using the following criteria: LDH \> 2 upper limit of normal; Protein/creatinine ratio \> 1 mg/mg or proteinuria ≥ 30 mg/dl in a random sample; Any multi-organ dysfunction except grade 1 acute kidney injury; sC5b-9 above the upper limit of normal; Grade II-IV acute graft-versus-host disease, systemic viral or bacterial infection, evaluated at any time up to 12 months after HSCT
Time frame: 3, 6, 9, 12 months (follow-up period)
Proportion of patients with multiple organ dysfunction
Assessed through specific definitions (Schoettler et al Transplant Cell Ther. 2023)
Time frame: 3, 6, 9, 12 months (follow-up period)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.